Tamarack Advisers, LP Gilead Sciences, Inc. Transaction History

Tamarack Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$57.72 - $65.01 $4.33 Million - $4.88 Million	-75,000 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$57.92 - $72.58 $4.34 Million - $5.44 Million	75,000 New	75,000 $4.46 Million
Q4 2018 Feb 11, 2019	SELL	$60.54 - $79.0 $10.6 Million - $13.8 Million	-175,000 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $1.78 Million - $1.97 Million	-25,000 Reduced 12.5%	175,000 $13.5 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $2.27 Million - $2.65 Million	35,000 Added 21.21%	200,000 $14.2 Million
Q1 2018 May 08, 2018	BUY	$72.84 - $88.8 $2.55 Million - $3.11 Million	35,000 Added 26.92%	165,000 $12.4 Million
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $355,750 - $417,600	5,000 Added 4.0%	130,000 $9.31 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $9.01 Million - $10.7 Million	125,000	125,000 $10.1 Million

1,903

1.02B

12M

9.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $112B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Tamarack Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Tamarack Advisers, LP with notifications on news.